# Gamma Biotherapeutics

Source: https://onco.cc/companies/gamma-biotherapeutics/  
OnCo record `gamma-biotherapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Gamma Biotherapeutics is a Portland company whose antibody, M3T01, blocks Fas ligand, a molecule many tumours use to kill the T cells that attack them. It is in an early trial in people with advanced cancers.

## Summary

Gamma Biotherapeutics, Inc., of Portland, Oregon, is a private clinical-stage company developing therapeutics that help the immune system fight cancer. Its lead programme M3T01 is a monoclonal antibody that neutralises Fas ligand, which many tumours produce and which triggers apoptosis in activated T cells; the company describes it as the first FasL-neutralising antibody to enter clinical trials. M3T01 is being tested alone and with pembrolizumab and other systemic therapies in a phase 1 trial in advanced solid tumours (NCT06719362), sponsored by Providence Health & Services. In fiscal year 2026 the National Cancer Institute funded its SBIR project on the clinical development of M3T01 for advanced cancers (1R44CA310416-01, USD 979,068).

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: GAMMA BIOTHERAPEUTICS, INC.
- HQ: Portland, OR
- Type: biotech
- Website: https://www.gammabiotherapeutics.com/

## Notes

- Read on gammabiotherapeutics.com, ClinicalTrials.gov (NCT06719362) and the NIH RePORTER record on 4 November 2026. The first-in-clinic statement is the company's own. No Fas ligand target record exists in the corpus.

## Sources

- Official website: https://www.gammabiotherapeutics.com/
- ClinicalTrials.gov: phase 1 trial of M3T01 (NCT06719362): https://clinicaltrials.gov/study/NCT06719362
- NIH RePORTER: 1R44CA310416-01: https://reporter.nih.gov/project-details/11315901

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [M3T01](https://onco.cc/drugs/m3t01/)

---
JSON: https://onco.cc/api/v1/entities/gamma-biotherapeutics.json